Associate Researcher, Xianghu Laboratory, China.
Dr. Guo Li is a cutting-edge genome engineer and associate researcher at Xianghu Laboratory, China. His pioneering work spans genome and RNA editing technologies, high-throughput functional gene screening, and CRISPR-based gene therapies. With a robust background in biochemistry and animal genetics, Dr. Li has made significant strides in RNA-targeting CRISPR systems and base editing technologies that enable precise correction of disease-causing mutations. His contributions are shaping the future of nucleic acid therapeutics and synthetic biology.
Professional Profile
Orcid
Education🎓
Dr. Guo Li obtained his Ph.D. in Biochemistry and Molecular Biology from China Agricultural University (2017–2021), where he focused on genome and RNA editing platforms. He earned his M.S. in Animal Genetics (2014–2016) and B.S. in Animal Biotechnology (2010–2014) from South China Agricultural University, developing foundational expertise in gene function and molecular diagnostics.
Experience 💼
Currently serving as an Associate Researcher at Xianghu Laboratory (since 2025), Dr. Li previously held the position of Postdoctoral Fellow and Assistant Researcher at Zhejiang University (2021–2023). His roles have involved leading synthetic biology innovations, developing RNA editors, and applying CRISPR-Cas systems to therapeutic models. His experience bridges academia and translational biotechnology, with multiple patents and high-impact publications.
Research Interests🔍
Dr. Li’s research interests center on three synergistic domains: (1) genome and RNA editing—developing tools for precise manipulation of mammalian genomes, (2) high-throughput functional gene screening using CRISPR-based technologies, and (3) gene therapy applications of CRISPR-Cas systems to model and correct genetic diseases. His work focuses on therapeutic delivery, target specificity, and clinical translation of RNA editors.
Awards🏆
Dr. Guo Li has received several prestigious accolades, including the Zhejiang High-Level Talent Training Program (Young Talent, 2025) and Finalist Award in the China Innovation & Entrepreneurship Competition (2024). He also secured 2nd and 3rd prizes in national innovation competitions and was recognized with Outstanding Staff Award at Zhejiang University (2022). During his academic career, he earned multiple First-Class Scholarships and awards for oral presentations and thesis excellence.
Top Noted Publications📄
Guo Li, et al.
Compact RNA editors with natural miniature Cas13j nucleases, Nature Chemical Biology, 2025, 21(2): 280–290.
🔗 Link | Cited by Google Scholar
Guo Li, et al.
A novel base editor SpRY-ABE8eF148A mediates efficient A-to-G base editing with reduced off-target effect, Molecular Therapy–Nucleic Acids, 2022, 31: 78–87.
🔗 Link
Guo Li, et al.
Transcription-wide impact by RESCUE-induced off-target SNVs in mammalian cells, Journal of Molecular Cell Biology, 2023, 15(2): mjad011.
🔗 Link
Guo Li, et al.
Developing PspCas13b-based enhanced RESCUE (eRESCUE) for RNA base editing, Cell Communication and Signaling, 2021, 19(1): 84.
🔗 Link
Ziwen Zheng, Guo Li, et al.
Preventing autosomal-dominant hearing loss in Bth mice using CRISPR/CasRx, Signal Transduction and Targeted Therapy, 2022, 7(1): 79.
🔗 Link
Yihan Wang, Guo Li, et al.
ecRESCUE: ecDHFR-regulated RESCUE with reduced off-targets, Cell Communication and Signaling, 2021, 19(1): 81.
🔗 Link
Yi Lu, Guo Li, et al.
Cellulose nanofibril matrix drives dynamic spheroid formation, Journal of Zhejiang University Science B, 2023, 24(10): 922–934.
🔗 Link
Shasha Ye, Guo Li, et al.
Stenotrophomonas maltophilia from the gut of plastic-eating Tenebrio molitor, Applied Biochemistry and Biotechnology, 2024, 196: 7805–7815.
🔗 Link
Guanglin Zhu, Guo Li, et al.
CRISPR-Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics, BioDesign Research, 2024, 6:0041.
🔗 Link
Yichen Yuan, Guo Li, et al.
Intelligent design of lipid nanoparticles for gene therapeutics, Molecular Pharmaceutics, 2025, 22: 1142–1159.
🔗 Link
Hongru Ma, Guo Li, et al.
AI-driven design of cell-penetrating peptides, Int. J. Peptide Research & Therapeutics, 2024, 30: 69.
🔗 Link